Literature DB >> 6762704

Serum concentration and clinical supervision in monitoring of lithium treatment.

A Amdisen.   

Abstract

Lithium therapy has become generally accepted as one of the major regimens for the treatment of acute mania as well as for the prevention of relapse in recurrent bipolar mood disorders. It is one drug for which monitoring is understood to be crucial, since the drug (1) has broad interindividual variability in dose-response, (2) often has a very narrow intraindividual therapeutic concentration index, (3) has a broad interindividual distribution of sensitivity and tolerance, and (4) is extremely dependent on stable kidney function for its successful and safe use. Determination of serum lithium concentration is the most important monitoring technique. However, the need for standardized clinical procedure coupled with corresponding reference ranges remains to be satisfied. The 12 hr standardized serum lithium is seen as the answer to this need, and the specifics of and indications for the procedure and appropriate reference values are given. The therapeutic range is suggested to lie between 0.30 and 1.30 mmoles/liter, with 1.50 mmoles/liter representing the lower limit of risk for intoxication. The treatment of initial and intercurrent lithium intoxication, which can reach life-threatening proportions, is also described.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6762704     DOI: 10.1097/00007691-198001000-00009

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  10 in total

1.  Comparison of lithium concentrations in red blood cells and plasma in samples collected for TDM, acute toxicity, or acute-on-chronic toxicity.

Authors:  M Camus; G Henneré; G Baron; G Peytavin; L Massias; F Mentré; R Farinotti
Journal:  Eur J Clin Pharmacol       Date:  2003-09-19       Impact factor: 2.953

2.  The value of therapeutic drug monitoring to the practising physician--an hypothesis in need of testing.

Authors:  G T McInnes
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

3.  Dosing strategies for lithium monotherapy in children and adolescents with bipolar I disorder.

Authors:  Robert L Findling; Vivian Kafantaris; Mani Pavuluri; Nora K McNamara; Jon McClellan; Jean A Frazier; Linmarie Sikich; Robert Kowatch; Jacqui Lingler; Jon Faber; Brieana M Rowles; Traci E Clemons; Perdita Taylor-Zapata
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-06       Impact factor: 2.576

4.  Reverse iontophoresis as a noninvasive tool for lithium monitoring and pharmacokinetic profiling.

Authors:  Benoît Leboulanger; Marc Fathi; Richard H Guy; M Begoña Delgado-Charro
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

5.  The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.

Authors:  Tetsu Tomita; Norio Yasui-Furukori; Taku Nakagami; Shoko Tsuchimine; Masamichi Ishioka; Ayako Kaneda; Norio Sugawara; Sunao Kaneko
Journal:  PLoS One       Date:  2014-05-23       Impact factor: 3.240

6.  Chronic lithium treatment elicits its antimanic effects via BDNF-TrkB dependent synaptic downscaling.

Authors:  Erinn S Gideons; Pei-Yi Lin; Melissa Mahgoub; Ege T Kavalali; Lisa M Monteggia
Journal:  Elife       Date:  2017-06-16       Impact factor: 8.140

7.  Prevalence of Therapeutic Drug Monitoring for Lithium and the Impact of Regulatory Warnings: Analysis Using Japanese Claims Database.

Authors:  Nobuhiro Ooba; Daisuke Tsutsumi; Naoko Kobayashi; Shinji Hidaka; Hiroyuki Hayashi; Taku Obara; Michihiro Satoh; Kiyoshi Kubota; Noriyasu Fukuoka
Journal:  Ther Drug Monit       Date:  2018-04       Impact factor: 3.681

8.  Monitoring of patients treated with lithium for bipolar disorder: an international survey.

Authors:  M Nederlof; E R Heerdink; A C G Egberts; I Wilting; L J Stoker; R Hoekstra; R W Kupka
Journal:  Int J Bipolar Disord       Date:  2018-04-14

9.  A new hyperpolarized 13C ketone body probe reveals an increase in acetoacetate utilization in the diabetic rat heart.

Authors:  Desiree Abdurrachim; Chern Chiuh Woo; Xing Qi Teo; Wei Xin Chan; George K Radda; Philip Teck Hock Lee
Journal:  Sci Rep       Date:  2019-04-02       Impact factor: 4.379

10.  The Collaborative Lithium Trials (CoLT): specific aims, methods, and implementation.

Authors:  Robert L Findling; Jean A Frazier; Vivian Kafantaris; Robert Kowatch; Jon McClellan; Mani Pavuluri; Linmarie Sikich; Stefanie Hlastala; Stephen R Hooper; Christine A Demeter; Denise Bedoya; Bernard Brownstein; Perdita Taylor-Zapata
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2008-08-12       Impact factor: 3.033

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.